Aclaris Therapeutics
ACRS
46 hedge funds and large institutions have $284M invested in Aclaris Therapeutics in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 5 reducing their positions, and 2 closing their positions.
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
380% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 5
35% more funds holding
Funds holding: 34 → 46 (+12)
2% more capital invested
Capital invested by funds: $277M → $284M (+$6.86M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$14.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$5.02M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.95M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$2.07M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.1M |
| 2 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$1.65M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$1.28M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$341K |
| 5 |
Citigroup
New York
|
-$149K |
ACRS Hedge Fund Activity: Q2 2016 in Review
46 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2016, worth a combined $284M — up 2.5% from $277M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ACRS positions and 2 closed out — a net gain of 12 holders — while 24 added to existing stakes and 5 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $14.8M. The largest seller was Fidelity Investments, cutting an estimated $20.1M.
- 46 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2016, up from 34 in Q1 2016.
- Funds reported $284M of Aclaris Therapeutics stock for Q2 2016, up 2.5% quarter-over-quarter.
- 14 funds opened new Aclaris Therapeutics positions in Q2 2016 and 2 closed out, a net change of +12 holders.
- The largest Aclaris Therapeutics buyer in Q2 2016 was Fidelity International, an estimated $14.8M added.
- The largest Aclaris Therapeutics seller in Q2 2016 was Fidelity Investments, an estimated $20.1M sold.
Based on aggregated 13F filings for Q2 2016.